Program
HLX319
A development code.
Its studies are mostly in Breast Neoplasms, led by Fosun Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 22 open or running | phase 1since Mar 22, 2026 | Mar 22, 2026 | Apr 23, 2027phase 1 · NCT07601620 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2026First study: phase 1 study in Health Adult SubjectsFirst studyNCT07495930 · 24 planned · China
- May 8, 2026Phase 1 study in Breast NeoplasmsNCT07601620 · 258 planned
Ahead
- Apr 23, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07601620
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07601620Breast Neoplasms | 1 | Not yet recruiting | Apr 23, 2027 | 258 |
| NCT07495930Health Adult Subjects · China | 1 | Not yet recruiting | Jul 1, 2026 | 24 |
How it is read
Names in the registry
- “HLX319”, 2 entries
Codes read as this program: HLX319.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.